311 related articles for article (PubMed ID: 22924551)
1. Modeling androgen receptor flexibility: a binding mode hypothesis of CYP17 inhibitors/antiandrogens for prostate cancer therapy.
Gianti E; Zauhar RJ
J Chem Inf Model; 2012 Oct; 52(10):2670-83. PubMed ID: 22924551
[TBL] [Abstract][Full Text] [Related]
2. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
Handratta VD; Vasaitis TS; Njar VC; Gediya LK; Kataria R; Chopra P; Newman D; Farquhar R; Guo Z; Qiu Y; Brodie AM
J Med Chem; 2005 Apr; 48(8):2972-84. PubMed ID: 15828836
[TBL] [Abstract][Full Text] [Related]
3. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel androgen receptor antagonists using structure- and ligand-based methods.
Li H; Ren X; Leblanc E; Frewin K; Rennie PS; Cherkasov A
J Chem Inf Model; 2013 Jan; 53(1):123-30. PubMed ID: 23278403
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.
Vasaitis T; Belosay A; Schayowitz A; Khandelwal A; Chopra P; Gediya LK; Guo Z; Fang HB; Njar VC; Brodie AM
Mol Cancer Ther; 2008 Aug; 7(8):2348-57. PubMed ID: 18723482
[TBL] [Abstract][Full Text] [Related]
6. Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001.
DeVore NM; Scott EE
Nature; 2012 Jan; 482(7383):116-9. PubMed ID: 22266943
[TBL] [Abstract][Full Text] [Related]
7. Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
Njar VC; Brodie AM
J Med Chem; 2015 Mar; 58(5):2077-87. PubMed ID: 25591066
[TBL] [Abstract][Full Text] [Related]
8. Learning from estrogen receptor antagonism: structure-based identification of novel antiandrogens effective against multiple clinically relevant androgen receptor mutants.
Liu B; Geng G; Lin R; Ren C; Wu JH
Chem Biol Drug Des; 2012 Mar; 79(3):300-12. PubMed ID: 22151347
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of novel steroidal imidazoles as dual inhibitors of AR/CYP17 for the treatment of prostate cancer.
Hou Q; He C; Lao K; Luo G; You Q; Xiang H
Steroids; 2019 Oct; 150():108384. PubMed ID: 30885648
[TBL] [Abstract][Full Text] [Related]
10. A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer.
Han D; Gao S; Valencia K; Owiredu J; Han W; de Waal E; Macoska JA; Cai C
Oncotarget; 2017 Jan; 8(4):6796-6808. PubMed ID: 28036278
[TBL] [Abstract][Full Text] [Related]
11. Targeting CYP17: established and novel approaches in prostate cancer.
Yap TA; Carden CP; Attard G; de Bono JS
Curr Opin Pharmacol; 2008 Aug; 8(4):449-57. PubMed ID: 18619560
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel androgen receptor antagonists: a hybrid approach of pharmacophore-based and docking-based virtual screening.
Liu J; Liu B; Guo G; Jing Y; Zhao G
Anticancer Drugs; 2015 Aug; 26(7):747-53. PubMed ID: 25933245
[TBL] [Abstract][Full Text] [Related]
13. Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells.
Soifer HS; Souleimanian N; Wu S; Voskresenskiy AM; Collak FK; Cinar B; Stein CA
J Biol Chem; 2012 Feb; 287(6):3777-87. PubMed ID: 22174412
[TBL] [Abstract][Full Text] [Related]
14. The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity.
Tamura H; Yoshioka M; Hasegawa M; Hosoda A; Matsugi M; Akamatsu M
Bioorg Med Chem; 2013 Jun; 21(11):2968-74. PubMed ID: 23611768
[TBL] [Abstract][Full Text] [Related]
15. Combined Ligand/Structure-Based Virtual Screening and Molecular Dynamics Simulations of Steroidal Androgen Receptor Antagonists.
Wang Y; Han R; Zhang H; Liu H; Li J; Liu H; Gramatica P
Biomed Res Int; 2017; 2017():3572394. PubMed ID: 28293633
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer.
Norris JD; Ellison SJ; Baker JG; Stagg DB; Wardell SE; Park S; Alley HM; Baldi RM; Yllanes A; Andreano KJ; Stice JP; Lawrence SA; Eisner JR; Price DK; Moore WR; Figg WD; McDonnell DP
J Clin Invest; 2017 Jun; 127(6):2326-2338. PubMed ID: 28463227
[TBL] [Abstract][Full Text] [Related]
17. CYP17 inhibitors for prostate cancer therapy.
Vasaitis TS; Bruno RD; Njar VC
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):23-31. PubMed ID: 21092758
[TBL] [Abstract][Full Text] [Related]
18. Computational prediction of new CYP17 inhibitors based on pharmacophore modeling, virtual screening and docking approach.
Haidar S; Hartmann RW
Pharmazie; 2017 Sep; 72(9):529-536. PubMed ID: 29441980
[TBL] [Abstract][Full Text] [Related]
19. Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists.
Guo C; Pairish M; Linton A; Kephart S; Ornelas M; Nagata A; Burke B; Dong L; Engebretsen J; Fanjul AN
Bioorg Med Chem Lett; 2012 Apr; 22(7):2572-8. PubMed ID: 22377517
[TBL] [Abstract][Full Text] [Related]
20. An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer.
Mohler ML; Sikdar A; Ponnusamy S; Hwang DJ; He Y; Miller DD; Narayanan R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
